Sign inCreate account

Report workspace tools

NCT07062588RECRUITINGanonymous

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)

Sponsor

Source record

Angitia Incorporated Limited

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

AGA2115, Placebo

Indication / condition

AI-normalized

Osteogenesis Imperfecta (OI)

Intervention

Source record

AGA2115, Placebo

Source & freshness

Source record

NCT ID

NCT07062588

Original source

ClinicalTrials.gov

Source last updated

May 29, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07062588

Title

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)

Sponsor

Angitia Incorporated Limited

Status

RECRUITING

Phase

PHASE2

Condition raw

Osteogenesis Imperfecta (OI)

Condition normalized

Osteogenesis Imperfecta (OI)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

AGA2115, Placebo

Target normalized

AGA2115, Placebo

Interventions

AGA2115, Placebo

Public preview

Source record

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07062588

Status

RECRUITING

Phase

PHASE2

Sponsor

Angitia Incorporated Limited

Executive brief

Investment-Ready Snapshot

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 29, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07062588

Indication

Osteogenesis Imperfecta (OI)

Modality

small molecule

Target

AGA2115, Placebo

Intervention

AGA2115, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.